WeHealth by Servier and Pathmaker Neurosystems collaborating to treat spasticity
WeHealth by Servier and Pathmaker Neurosystems have formed a partnership to develop and commercialise Pathmaker’s MyoRegulator device, a non-invasive treatment for spasticity.
WeHealth by Servier and Pathmaker Neurosystems have formed a partnership to develop and commercialise Pathmaker’s MyoRegulator device, a non-invasive treatment for spasticity.
Spasticity is a chronic condition characterised by painful muscle contractions and is common in patients following stroke, spinal cord injury, traumatic brain injury, cerebral palsy, multiple sclerosis and other neurological disorders. It affects an estimated 12 million people worldwide. Current treatments of the disorder include pharmacological agents, botulinum toxin injections and intrathecal baclofen, which are often costly and result in undesired side-effects.
The MyoRegulator system delivers synchronised stimulation at two sites along the neural axis via two pairs of disposable skin-surface electrodes. Through precisely sequenced and targeted multi-site stimulation directed at the spinal outflow and peripheral nerve leading to the muscle of interest, it modulates neural activity to suppress hyperexcitable spinal neurons involved in spasticity. Clinical results from a recently completed US study at Northwell Health evaluating the effect of MyoRegulator treatment on post-stroke spasticity were presented at the Society for Neuroscience meeting in November 2018.
The MyoRegulator is currently undergoing clinical trial for non-invasive treatment of spasticity secondary to stroke at the Brain and Spine Institute of the Pitié-Salpêtrière Hospital in Paris, France. WeHealth will fund the trial and a further, larger European clinical trial intended to support reimbursement coverage. WeHealth will then distribute the device globally, excluding the US and Japan.
Dr Nader Yaghoubi, President and CEO of PathMaker said: “This significant partnership will provide a large number of patients with access to this breakthrough non-invasive treatment through WeHealth’s international presence in more than 100 countries worldwide.”